Benzinga | Feb 25, 2021 07:15AM EST

Kala Pharmaceuticals Q4 EPS $(0.55) Misses $(0.46) Estimate, Sales $2.24M Miss $2.39M Estimate

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 12.7 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $2.24 million which missed the analyst consensus estimate of $2.39 million by 6.36 percent. This is a 89.66 percent increase over sales of $1.18 million the same period last year.